Here, from a structural viewpoint, we describe a highly cross-reactive anti-HLA class I mAb (B1.23.2) that can block inhibitory KIR/HLA interactions and has the potential to add to a multipronged approach to tumor treatment. Here, KIR3DL1 is linked to neoplasm.